Black Diamond Therapeutics Announces Pipeline Prioritization and Workforce RealignmentGlobeNewsWire • 04/25/22
Black Diamond Therapeutics Announces First Patient Dosed in Phase 1 Study of BDTX-1535, a MasterKey Inhibitor of EGFR for the Treatment of Glioblastoma and Non-Small Cell Lung CancerGlobeNewsWire • 04/18/22
Black Diamond Therapeutics to Present at the Canaccord Genuity Horizons in Oncology Virtual ConferenceGlobeNewsWire • 04/07/22
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/17/22
Black Diamond Therapeutics to Participate at the Cowen 42nd Annual Health Care ConferenceGlobeNewsWire • 03/02/22
Black Diamond Therapeutics Appoints Elizabeth Montgomery as Chief People OfficerGlobeNewsWire • 02/22/22
Black Diamond Therapeutics Announces FDA Allowance of IND Application for BDTX-1535, A MasterKey Inhibitor of EGFR for the Treatment of Gliobastoma and Non-Small Cell Lung CancerGlobeNewsWire • 01/11/22
Black Diamond Therapeutics Announces Strategic Priorities and Expected Milestones for 2022GlobeNewsWire • 01/10/22
Black Diamond Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/05/22
Black Diamond Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/08/21
Black Diamond Therapeutics Presents Preclinical Data on BDTX-1535, BRAF, and FGFR Programs at the 33rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsGlobeNewsWire • 10/08/21
Black Diamond Therapeutics to Present Pre-Clinical Data on BDTX-1535, BRAF, and FGFR Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsGlobeNewsWire • 09/30/21
Black Diamond Therapeutics to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare ConferenceGlobeNewsWire • 09/21/21
Black Diamond Therapeutics and OpenEye Scientific Announce Collaboration to Expand MAP Drug Discovery PlatformGlobeNewsWire • 09/21/21
Black Diamond Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/12/21
Black Diamond Therapeutics Announces Appointment of Mark Velleca, M.D., Ph.D. to Board of DirectorsGlobeNewsWire • 08/10/21
Black Diamond Therapeutics Stock Plunges On Safety Signals In Solid Tumor Study Of BDTX-189Benzinga • 05/20/21
Black Diamond Therapeutics Presents Phase 1 Pharmacokinetic, Safety, and Preliminary Efficacy Data of BDTX-189 in Advanced Solid Tumors Harboring EGFR or HER2 AlterationsGlobeNewsWire • 05/19/21
Black Diamond Therapeutics to Host Webcast Presentation of Data From Phase 1 Dose-Escalation Portion of MasterKey-01 Clinical TrialGlobeNewsWire • 05/17/21
Black Diamond Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/07/21
Black Diamond Therapeutics to Present Phase 1 BDTX-189 Data in Advanced Solid Tumors at American Society of Clinical OncologyGlobeNewsWire • 04/28/21